Please use this identifier to cite or link to this item:
|Title:||From snake venom toxins to therapeutics - Cardiovascular examples|
Toxins to drugs
Toxins to therapeutics
|Source:||Koh, C.Y., Kini, R.M. (2012-03-15). From snake venom toxins to therapeutics - Cardiovascular examples. Toxicon 59 (4) : 497-506. ScholarBank@NUS Repository. https://doi.org/10.1016/j.toxicon.2011.03.017|
|Abstract:||Snakes have fascinated the imaginations of people since the dawn of civilization. Their deadly venoms cause significant mortality and morbidity worldwide, and strike fear in most of us. Snake venoms contain a huge variety of molecules affecting vital physiological systems, and scientists are turning some of these life-threatening toxins into a source of life-saving therapeutics. Since the approval of captopril - the first drug based on snake venom protein - more than 30 years ago, snake venom toxins have become a valuable natural pharmacopeia of bioactive molecules that provide lead compounds for the development of new drugs. Many toxins are being explored and developed into drugs for the treatment of conditions such as hypertension, thrombosis and cancer. A number of new drugs are constantly emerging from this pipeline. In this review, we briefly highlight the molecular basis of developing therapeutic agents, such as Captopril, Tirofiban, and Eptifibatide, from snake venom proteins. We also discuss the successes and failures as an update to the advances in the field. © 2011 Elsevier Ltd.|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Mar 7, 2018
WEB OF SCIENCETM
checked on Jan 24, 2018
checked on Mar 11, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.